The UMCG is going to study a potential COVID-19 vaccine:
the AKS-452 vaccine produced by Akston Biosciences in the United States.
The goal of the study is to research the safety and tolerability of and the reaction of the immune system to the vaccine. For the study, the UMCG is looking for 176 healthy volunteers aged between 18 and 65 who are willing to be vaccinated with the potential vaccine.
The Akston Biosciences vaccine is a ‘recombinant subunit vaccine’. In this type of vaccine, the actual coronavirus (weakened or alive) is not used. The vaccine is made from a particle of the virus, the spike protein, which is fused with a protein fragment from a human antibody. The vaccine is contained in a liquid or adjuvant that strengthens the immune response.
The human body recognizes that the spike protein belongs to the coronavirus and initiates a defence mechanism, through which antibodies and T cells are produced. Through this technique, a natural reaction against viral infection is imitated and the body’s immune system is activated. The advantage of this type of vaccine is that it does not contain any genetic material of the virus and it is therefore impossible for the virus to multiply in the body.
The vaccine has already been extensively tested in animal models for COVID-19 infections, in which it appears to be effective and safe. The next phase is to research the safety and tolerability of and the reaction of the immune system to the vaccine in humans.
The UMCG is looking for 176 healthy volunteers, aged above 18 and below 65, who have not yet been infected with SARS-CoV-2 or received another potential or established coronavirus vaccine. The research participants will receive either one or two doses of the potential vaccine to establish the dosage needed to achieve a sufficient number of antibodies. Participants will still be able to receive another coronavirus vaccine at a later stage.
About Akston Biosciences
Akston Biosciences is located in Beverly, Massachusetts and is specialized in the development of new fusion proteins to develop and produce new biological treatments for the prevention of type 1 diabetes, for long-acting insulin treatment and for vaccines. The AKS-452 vaccine is based on this technique, which uses the conventional production techniques of antibodies. More information can be found at
A PhD dissertation consisting of more than 1100 pages and covering a total of 31 chapters. UMCG PhD-candidate Arno Bourgonje (26) probably wrote the most voluminous medical PhD dissertation ever published in the Netherlands.
Under the supervision...
In this video lecture from the University of the Netherlands, neuroscientist Roelof Hut (University of Groningen, UMCG) talks about the biological clock. Can you become a morning person? Watch this video lecture for tips!
Blue Monday is the name that was once given to the supposedly most depressing day of the year. On this day, the UG would like to draw attention to research on depression. Whether there is a relationship between loneliness and depression, what exactly...
The UG website uses functional and anonymous analytics cookies. Please answer the question of whether or not you want to accept other cookies (such as tracking cookies).
If no choice is made, only basic cookies will be stored. More information